Work

Supplementary Information from A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors

Year: 2023

Type: supplementary-materials

Abstract: Additional Methods; Tables and Figure [1]Supplementary Methods: Contrast-enhanced ultrasound (CE-US) [2]Supplementary Table S1. Pharmacokinetic characteristics of PF-03446962 following single-dose administration in cycle 1 [3]Supplementary Table S2. Best overall tumor response in patients treated with PF-03446962 [4]Supplementary Figure S1. Telangiectasia observed in patients treated with PF-03446962.

DOI: 10.1158/1078-0432.22456403

Authors: Laura W. Goff, Roger B. Cohen, Jordan D. Berlin, Filippo G. de Braud, Andrej Lyshchik, Cristina Noberasco, Francesco Bertolini, Marina Carpentieri, Corrado Gallo Stampino, Antonello Abbattista, Erjan Wang, Hossein Borghaei

Language: English

Topic: TGF-β signaling in diseases

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361912126

Cites:

Cited by:

Related to: 10